

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/615,044	07/08/2003	Paul Andrew Benjes	223505	3936
23460	7590 01/04/2006		EXAMINER	
LEYDIG VOIT & MAYER, LTD			SOLOLA, TAOFIQ A	
TWO PRUDENTIAL PLAZA, SUITE 4900 180 NORTH STETSON AVENUE CHICAGO, IL 60601-6780		900	ART UNIT	PAPER NUMBER
			1626	

DATE MAILED: 01/04/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

· •			
	Application No.	Applicant(s)	
	10/615,044	BENJES ET AL.	
Office Action Summary	Examiner	Art Unit	
	Taofiq A. Solola	1626	
The MAILING DATE of this communication app Period for Reply	pears on the cover sheet with the c	orrespondence address	
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period v - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tim vill apply and will expire SIX (6) MONTHS from , cause the application to become ABANDONEI	1. lely filed the mailing date of this communication. D (35 U.S.C. § 133).	
Status			
 1) Responsive to communication(s) filed on 10/27 2a) This action is FINAL. 2b) This 3) Since this application is in condition for alloware closed in accordance with the practice under Exercise. 	action is non-final. nce except for formal matters, pro		
Disposition of Claims			
4) Claim(s) 1,8,9,11-17 and 19-23 is/are pending 4a) Of the above claim(s) is/are withdray 5) Claim(s) is/are allowed. 6) Claim(s) 1,8,9,11-17 and 19-23 is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) are subject to restriction and/or Application Papers 9) The specification is objected to by the Examine 10) The drawing(s) filed on is/are: a) access applicant may not request that any objection to the	wn from consideration. r election requirement. r. epted or b) □ objected to by the E		
Replacement drawing sheet(s) including the correct			
11) The oath or declaration is objected to by the Ex			
Priority under 35 U.S.C. § 119			
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority documents 2. Certified copies of the priority documents 3. Copies of the certified copies of the priority application from the International Bureau * See the attached detailed Office action for a list	s have been received. s have been received in Application rity documents have been receive u (PCT Rule 17.2(a)).	on No ed in this National Stage	
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal P 6) Other:		

Application/Control Number: 10/615,044

Art Unit: 1626

Claims 1, 8-9, 11-17, 19-23 are pending in this application.

Claims 2-7, 10, 18 are pending in this application.

Request for Continued Examination

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.117(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 10/27/05 has been entered.

Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter, which the applicant regards as his invention.

Claims 12-13, are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

The claims improperly depend from claim 11 for failure to limit the scope of claim 11. Steps (e), (f) and (g) are in the same sequential order in claims 11-13. By deleting claims 12-13 the rejection would be overcome.

Application/Control Number: 10/615,044

Art Unit: 1626

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 1, 8-9, 11-17, 19-23 are rejected under 35 U.S.C. 103(a) as being unpatentable over Kayakiri et al., Chem. Bull. Vol. 39, No. 6 (1991), pages 1392-1396, (Kayakiri et al., I) individually or in view of Kayakiri et al., Tetrahedron Let, Vol. 31, No. 2 (1990), pages 225-226 (Kayakiri et al., II), in view of Morrison et al., Org. Chem., 3rd edition, (1974), page 759.

Applicant claims a process of making kifunensine from compounds of formula I, and a process of making compounds of formula I comprising steps (a) to (d) set forth in claim 1, steps (e) to (i) set forth in claim 11 and steps (a) to (g) in claim 17. In preferred embodiment, applicant claims specific reagents and how the process is performed. In other embodiment, applicant changes the sequence of the reaction steps or combines steps/reagents from both prior arts – selective combination.

Determination of the scope and content of the prior art (MPEP 32141.01)

Kayakiri et al., teach a similar process of making kifunensine from compounds of formula I, and a process of making compounds of formula I. Kayakiri et al., teach all the instantly claimed steps, the reagents and reaction conditions. See pages 1392-1394, charts 1-7 and the experimental sections on pages 1394-1396 (first prior art) and pages 225-226 of second prior art.

Ascertainment of the difference between the prior art and the claims (MPEP 32141.02)

Application/Control Number: 10/615,044

Art Unit: 1626

The difference between the instant invention and that of Kayakiri et al., is that applicant changes the sequential order of the reaction steps or combines steps/reagents from both prior arts - selective combination. Also, applicant now use N-acetyl protected D-mannosamine as the starting material instead of oxamoyl as N-protecting group by Kayakiri et al.

Finding of prima facie obviousness---rational and motivation (MPEP 32142.2413)

However, in a telephonic interview with the Examiner on/about 9/14/05, applicant admitted the sequence of the steps is not important and may vary. Selective combination of prior art(s) teaching is prima facie obvious. There is no indication of an interaction between the steps such that one of ordinary skill in the art would have any doubts that the selective combinations could not be made. *In re Mostovych*, 144 USPQ 38 (CCPA, 1964). Morrison et al., Org. Chem., 3rd edition, (1974), page 759, teach using acetate to protect N. See page 759, lines 1-2 4 of paragraph 7. Therefore, the instant invention is prima facie obvious from the teachings of the prior arts. One of ordinary skill in the art would have known to use N-acetyl protected D-mannosamine as the starting material instead of oxamoyl as N-protecting group at the time the invention was made. The motivation is from knowing that acetate is a N-protecting group.

Applicant's arguments filed 12/16/04 have been fully considered but they are not persuasive. In the claims applicant added N-acetyl as the protecting group at position 6, and contends that the prior art use N-oxamoyl protecting group. Applicant asserts that N-acetyl allows for a large-scale production. This is not persuasive because there is no support for this assertion in the specification, and using an analogous starting material in a well-known process is

Application/Control Number: 10/615,044 Page 5

Art Unit: 1626

prima facie obvious. *In re Durden*, 226 USPQ 359 (1985). In the instant N-acetyl and N-oxamoyl are analogous starting materials.

Telephone Inquiry

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Taofiq A. Solola, PhD, JD, whose telephone number is (571) 272-0709.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Mr. Joseph McKane, can be reached on (571) 272-0699. The fax phone number for this Group is (571) 273-8300.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (571) 272-1600.

TAÓFIQ SOLOLA PRIMARY EXAMINER

Group 1626

December 20, 2005